Humana Inc. · Healthcare
Survives a correction-sized 3-point cut to analyst growth.
At a 1.9% margin the price requires 5.3% 3y revenue CAGR against 13.8% consensus, a cushion of +6.6pt versus a 0pt correction cut. Cushion clears the cut, so the price survives the correction on consensus estimates. The co-mention is noise; the risk is the MA policy that hit UNH this week.
Breaks if: Star ratings or the CMS rule that hit UNH reach Humana's MA book. We re-check this against analyst estimates every evening.
10 years, at a 2% margin analysts expect
+9.2%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
26 published targets, set before the drop
Linked to GOOGL, ORCL
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 148% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 10, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 46th percentile of 26 published models, almost exactly at the median, meaning the market broadly endorses the middle-ground forecast and refuses to pay for either the most optimistic recovery scenarios or the most pessimistic structural declines.
Whether Humana can actually restore its Medicare Advantage Star Ratings to top-quartile by 2028 to unlock bonus payments and validate its margin targets, a question that cannot be settled with the available wired data.
What the price refuses to pay for, and the full reconstruction, on the HUM quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names